Genprex $GNPX Seeks Clinical Gains with REQORSA in Lung Cancer Trials

The biotech sector often sees speculative interest in companies pursuing novel therapies for high-need areas like lung cancer, with Genprex (NASDAQ: GNPX) recently drawing attention for its lead candidate, REQORSA (quaratusugene ozeplasmid). This gene therapy is under evaluation in clinical trials targeting both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), two of the most challenging oncology indications. While market sentiment, as reflected in discussions on platforms like X from accounts such as ACInvestorBlog, occasionally highlights past price movements, the real focus for investors should be the clinical progress and data emerging from Genprex’s ongoing studies. This analysis dives into the latest updates on REQORSA, assessing its potential against the backdrop of a competitive and complex therapeutic landscape.

Clinical Trials Update: Acclaim-1 and Acclaim-3 in Focus

Genprex is currently advancing REQORSA through multiple clinical trials, with the Acclaim-1 and Acclaim-3 studies being the most prominent for NSCLC and SCLC, respectively. Acclaim-1, a Phase 1/2 trial, targets NSCLC patients who have progressed after prior therapies, combining REQORSA with AstraZeneca’s Tagrisso (osimertinib). Recent updates from late 2024 indicate positive signals, including prolonged progression-free survival in select patients, though the sample size remains limited at this stage. The company reported these findings in August 2024, underscoring the therapy’s potential to address resistance mechanisms in EGFR-mutated NSCLC.

Meanwhile, Acclaim-3, also a Phase 1/2 trial, focuses on extensive-stage SCLC (ES-SCLC) in combination with Roche’s Tecentriq (atezolizumab) as a maintenance therapy. By October 2024, Genprex received clearance to escalate to the highest dose in this trial, a procedural milestone suggesting tolerable safety profiles thus far. More notably, a poster presentation at the 2025 ASCO Annual Meeting, announced in May 2025, detailed the trial design and early insights, including partial remission in some patients under maintenance therapy. These updates, while encouraging, are preliminary and await larger cohort data to confirm efficacy trends.

Therapeutic Context: A Crowded and Evolving Field

Lung cancer remains a critical area of unmet need, with NSCLC accounting for approximately 85% of cases and SCLC representing a smaller but particularly aggressive subset. Current standards of care, including checkpoint inhibitors and targeted therapies, have improved outcomes but often face challenges with resistance and relapse. Gene therapies like REQORSA, which aims to restore tumour suppressor gene function, represent a novel approach. Specifically, REQORSA targets the TUSC2 gene, believed to play a role in inhibiting cancer cell growth. Preclinical data suggests potential synergy with existing immunotherapies, a hypothesis now under clinical scrutiny.

However, the competitive landscape is formidable. For NSCLC, therapies targeting EGFR mutations, such as Tagrisso, dominate, while SCLC treatments have seen recent advances with antibody-drug conjugates and biomarker-driven approaches. Genprex’s challenge lies in demonstrating not just efficacy but also a meaningful differentiation in patient outcomes. The early data from Acclaim-1 and Acclaim-3, while intriguing, must be contextualised against these benchmarks. Investors should note that Phase 1/2 results often overpromise, and late-stage failures are not uncommon in oncology.

Financial Position and Market Dynamics

Turning to Genprex’s financial health, the company’s latest filings provide a snapshot of its capacity to sustain clinical development. As of the Q1 2025 reporting period (January to March), Genprex reported cash reserves sufficient to fund operations into mid-2025, though exact figures remain subject to ongoing burn rates tied to trial expenses. Research and development costs, a significant portion of expenditure, increased by approximately 15% year-over-year from Q1 2024 to Q1 2025, reflecting intensified trial activity. This trajectory aligns with a company in active clinical phases but underscores the need for additional capital or partnerships to reach commercialisation.

Market dynamics also warrant scrutiny. Biotech stocks, particularly those in early clinical stages, are prone to volatility driven by trial updates and broader sector sentiment. Genprex’s share price has experienced fluctuations, with historical spikes often tied to clinical news rather than fundamental shifts in valuation. While past surges are of anecdotal interest, they offer little predictive value for future performance. The focus should remain on upcoming data readouts expected in late 2025 from both Acclaim trials, which could serve as catalysts if positive.

Risks and Outlook

Several risks temper optimism around REQORSA. First, the small sample sizes in current trial phases limit statistical robustness, and adverse events, though not widely reported to date, could emerge at higher doses. Second, the gene therapy field, while innovative, faces regulatory and manufacturing hurdles that could delay timelines. Finally, competition from established players with deeper resources poses a constant threat to smaller firms like Genprex.

That said, the outlook is not without merit. If REQORSA can demonstrate durable responses in resistant patient populations, particularly in SCLC where options remain scarce, it could carve a niche. The synergy with existing therapies like Tecentriq also offers a strategic angle, potentially easing adoption if approved. For now, cautious monitoring of trial milestones is advised over speculative enthusiasm.

In conclusion, Genprex’s work with REQORSA marks a noteworthy effort in the lung cancer space, with early clinical signals providing a basis for measured interest. The road ahead, however, is paved with scientific and financial challenges that will test the company’s resilience. As data accumulates through 2025, the true potential of this therapy will come into sharper focus, offering either validation or a sobering reminder of oncology’s high bar for success.

References

• ACInvestorBlog. (2024, May 1). [Post on X]. Retrieved from https://x.com/ACInvestorBlog/status/1809975255005286806
• ACInvestorBlog. (2024, September 13). [Post on X]. Retrieved from https://x.com/ACInvestorBlog/status/1835308061608550909
• ACInvestorBlog. (2025, March 5). [Post on X]. Retrieved from https://x.com/ACInvestorBlog/status/1943204042399735987
• ACInvestorBlog. (2025, March 5). [Post on X]. Retrieved from https://x.com/ACInvestorBlog/status/1943279429855158450
• ACInvestorBlog. (2022, May 5). [Post on X]. Retrieved from https://x.com/ACInvestorBlog/status/1522245814822871041
• AJMC. (2023, November 13). Is a new era of SCLC, LCNEC treatments on the horizon?. Retrieved from https://www.ajmc.com/view/is-a-new-era-of-sclc-lcnec-treatments-on-the-horizon-
• American Cancer Society. (2025). Key statistics for lung cancer. Retrieved from https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html
• Applied Clinical Trials Online. (2024, August 23). REQORSA demonstrates promising results treating patients with Small Cell Lung Cancer, Non-Small Cell Lung Cancer. Retrieved from https://www.appliedclinicaltrialsonline.com/view/reqorsa-demonstrates-promising-results-treating-patients-small-cell-lung-cancer-non-small-cell-lung-cancer
• BioSpace. (2025, May 29). Genprex to present trial design of Acclaim-3 clinical trial evaluating REQORSA® gene therapy in small cell lung cancer at 2025 ASCO annual meeting. Retrieved from https://www.biospace.com/press-releases/genprex-to-present-trial-design-of-acclaim-3-clinical-trial-evaluating-reqorsa-gene-therapy-in-small-cell-lung-cancer-at-2025-asco-annual-meeting
• Clinical Trials Arena. (2024, October 16). Genprex advances to highest dose in Phase I Acclaim-3 trial of Reqorsa. Retrieved from https://www.clinicaltrialsarena.com/news/genprex-advances-highest-dose-trial/
• Genprex, Inc. (2024, August 14). Genprex announces positive clinical study updates from Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials in lung cancer. Retrieved from https://www.prnewswire.com/news-releases/genprex-announces-positive-clinical-study-updates-from-acclaim-1-and-acclaim-3-phase-12-clinical-trials-in-lung-cancer-302221892.html
• Genprex, Inc. (2025, February 13). Genprex collaborators find NPRL2 gene therapy using Oncoprex delivery system is a potential treatment for anti-PD1 resistant Non-Small Cell Lung Cancer. Retrieved from https://www.prnewswire.com/news-releases/genprex-collaborators-find-nprl2-gene-therapy-using-oncoprex-delivery-system-is-a-potential-treatment-for-anti-pd1-resistant-non-small-cell-lung-cancer-302375899.html
• Genprex, Inc. (2025, May 10). Quarterly Report for Q1 2025. Retrieved from https://ir.genprex.com/static-files/q1-2025-genprex-report
• Genprex, Inc. (2025, May 29). Genprex to present trial design of Acclaim-3 clinical trial evaluating Reqorsa gene therapy in small cell lung cancer at 2025 ASCO annual meeting. Retrieved from https://www.prnewswire.com/news-releases/genprex-to-present-trial-design-of-acclaim-3-clinical-trial-evaluating-reqorsa-gene-therapy-in-small-cell-lung-cancer-at-2025-asco-annual-meeting-302467469.html
• OncLive. (2024, August 28). Looking ahead in NSCLC: oncodrivers and targeted therapies. Retrieved from https://onclive.com/view/looking-ahead-in-nsclc-oncodrivers-and-targeted-therapies
• OncLive. (2023, June 29). Treatment sequencing in neuroendocrine tumors. Retrieved from https://onclive.com/view/treatment-sequencing-in-neuroendocrine-tumors
• Stock Titan. (n.d.). Genprex Inc (GNPX) Overview. Retrieved from https://www.stocktitan.net/overview/GNPX/